<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rheumatol Int</journal-id><journal-id journal-id-type="iso-abbrev">Rheumatol. Int</journal-id><journal-title-group><journal-title>Rheumatology International</journal-title></journal-title-group><issn pub-type="ppub">0172-8172</issn><issn pub-type="epub">1437-160X</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7360125</article-id><article-id pub-id-type="publisher-id">4639</article-id><article-id pub-id-type="doi">10.1007/s00296-020-04639-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3224-1151</contrib-id><name><surname>Shah</surname><given-names>Sanket</given-names></name><address><email>sanketimmunology@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2121-0942</contrib-id><name><surname>Danda</surname><given-names>Debashish</given-names></name><address><email>debashish.danda@cmcvellore.ac.in</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3643-3989</contrib-id><name><surname>Kavadichanda</surname><given-names>Chengappa</given-names></name><address><email>doc.chengappa@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3153-4166</contrib-id><name><surname>Das</surname><given-names>Saibal</given-names></name><address><email>saibaldas123@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8091-1952</contrib-id><name><surname>Adarsh</surname><given-names>M. B.</given-names></name><address><email>adarshmb@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1518-6031</contrib-id><name><surname>Negi</surname><given-names>Vir Singh</given-names></name><address><email>vsnegi22@yahoo.co.in</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.414953.e</institution-id><institution-id institution-id-type="ISNI">0000000417678301</institution-id><institution>Department of Clinical Immunology, </institution><institution>Jawaharlal Institute of Postgraduate Medical Education and Research, </institution></institution-wrap>Pondicherry, India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.11586.3b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1767 8969</institution-id><institution>Department of Clinical Immunology and Rheumatology, </institution><institution>Christian Medical College, </institution></institution-wrap>Vellore, India </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.414953.e</institution-id><institution-id institution-id-type="ISNI">0000000417678301</institution-id><institution>Department of Clinical Pharmacology, </institution><institution>Jawaharlal Institute of Postgraduate Medical Education and Research, </institution></institution-wrap>Pondicherry, India </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>7</month><year>2020</year></pub-date><fpage>1</fpage><lpage>16</lpage><history><date date-type="received"><day>3</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The coronavirus disease-2019 (COVID-19) pandemic is likely to pose new challenges to the rheumatology community in the near and distant future. Some of the challenges, like the severity of COVID-19 among patients on immunosuppressive agents, are predictable and are being evaluated with great care and effort across the globe. A few others, such as atypical manifestations of COVID-19 mimicking rheumatic musculoskeletal diseases (RMDs) are being reported.&#x000a0;Like in many other viral infections, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can potentially lead to an array of rheumatological and autoimmune manifestations by molecular mimicry (cross-reacting epitope between the virus and the host), bystander killing (virus-specific CD8&#x02009;+&#x02009;T cells migrating to the target tissues and exerting cytotoxicity), epitope spreading, viral persistence (polyclonal activation due to the constant presence of viral antigens driving immune-mediated injury) and formation of neutrophil extracellular traps.&#x000a0;In addition, the myriad of antiviral drugs presently being tried in the treatment of COVID-19 can result in several rheumatic musculoskeletal adverse effects. In this review, we have addressed the possible spectrum and mechanisms of various autoimmune and rheumatic musculoskeletal manifestations that can be precipitated by COVID-19 infection, its therapy, and the preventive strategies to contain the infection.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Coronavirus disease-2019 (COVID-19)</kwd><kwd>Rheumatic musculoskeletal diseases (RMDs)</kwd><kwd>Autoimmunity</kwd><kwd>Rheumatology</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par59">The coronavirus disease-2019 (COVID-19) pandemic has taken a heavy toll on the healthcare system across the world. With a global incidence of over six million, the mortality rate so far has been approximately 6.5% [<xref ref-type="bibr" rid="CR1">1</xref>]. Though a few countries have succeeded in containing the spread of the virus, the overall incidence of fresh infections is still on the rise. Moreover, with no vaccine or definitive treatment in sight [<xref ref-type="bibr" rid="CR2">2</xref>], the health care systems across the world are strained and are staring at an uncertain future and a long-term coexistence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) with the human host has been anticipated.</p><p id="Par60">From the perspective of a rheumatologist, there are concerns regarding compelling actions and future preparedness for facing COVID-19 and its after effects. We have always considered rheumatic musculoskeletal diseases (RMDs) as conditions that are precipitated when a genetically susceptible host encounters specific environmental triggers. Our firsthand knowledge of the host-environment interaction in RMD until now was limited to epidemiological studies related to small infectious outbreaks like the Chikungunya epidemic which has given us insights into various post-infectious RMD manifestations. The COVID-19 pandemic, in contrast to these relatively small occurrences, is a mammoth event in the history of humankind. The infection has spread across all large countries affecting people from all age groups. Such an infection is likely to have long-term consequences, and RMDs could be a major fallout given the quantum of immune dysregulation the virus is known to cause [<xref ref-type="bibr" rid="CR3">3</xref>]. There are already reports of post-COVID-19 autoimmunity with an increase in the incidence of Kawasaki disease [<xref ref-type="bibr" rid="CR4">4</xref>] and Guillain-Barr&#x000e9; syndrome [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. In a global attempt to curb this pandemic, a variety of drugs with varying mechanisms of action are being tried. While some of these drugs are known to cause adverse effects mimicking RMDs and other autoimmune diseases, there is a lack of information for the majority of them. There are also concerns regarding the right approach to treat existing rheumatic diseases and about the outcome of infection among those on immunosuppressive agents. This and many more challenges faced by patients with RMDs and their care providers during the COVID-19 pandemic are being addressed by the Global Alliance Registry and the COVID-19 database of the European League Against Rheumatism (EULAR); mining these data will serve as a guide in the future for the management of patients with RMDs [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par61">The COVID-19 pandemic has undoubtedly uncovered the strengths of global collaborations, effective communication, and dissemination of information. Unless we prepare and foresee the likely new set of RMDs and the possible mimics of RMDs [<xref ref-type="bibr" rid="CR8">8</xref>] due to this pandemic, we are going to fail in delivering care to our patients. We have recently learned the costs of being underprepared when challenged with the rheumatological manifestation [<xref ref-type="bibr" rid="CR9">9</xref>] resulting from the use of immune checkpoint inhibitors in cancer treatment. The initial dilemma on the management plan and prognosis of these conditions set the rheumatology community on a backfoot [<xref ref-type="bibr" rid="CR10">10</xref>]. Keeping this context in mind, it is time to pool all our existing knowledge and resources to prepare for any rheumatological fallout of COVID-19 and its treatment, which may have left behind its footprints even in the post-COVID-19 era.</p></sec><sec id="Sec2"><title>Objective and search strategy</title><p id="Par62">Our objective was to narrate various autoimmune and rheumatic manifestations that are associated with COVID-19 and the drugs used in its treatment.&#x000a0;We conducted a literature search for articles since inception and published until 20 May 2020 in the English language using the Medline database. The search terms used in various combinations were: &#x0201c;coronavirus disease-19&#x0201d;, &#x0201c;COVID-19&#x0201d;, &#x0201c;SARS-CoV-2&#x0201d;, &#x0201c;rheumatic&#x0201d;, &#x0201c;autoimmune&#x0201d;, &#x0201c;musculoskeletal&#x0201d;, &#x0201c;clinical&#x0201d;, &#x0201c;manifestations&#x0201d;, &#x0201c;antivirals&#x0201d;, and &#x0201c;vaccines&#x0201d;. Additionally, we performed a focused literature search in the same database for articles on drugs used in COVID-19. We included original research articles, reviews, viewpoints, opinions, commentaries, case series, and case reports as relevant to our objective. The search strategy was used to obtain the titles and the abstracts of the relevant studies which were initially screened, and if necessary, the full text was retrieved to determine the suitability. The references and related citations for the resulting articles were also reviewed for pertinence. Finally, the information was synthesized in a logical sequence with expert inputs from the senior authors.</p></sec><sec id="Sec3"><title>Clinical presentations of COVID-19</title><p id="Par63">SARS-CoV-2 enters the cells through angiotensin-converting enzyme 2 (ACE2) receptors located on the nasopharyngeal and bronchial mucosa, and on alveolar pneumocytes in the lungs [<xref ref-type="bibr" rid="CR11">11</xref>]. The smooth muscles of the arterial walls and endothelial cells of the veins in every organ of the body express ACE2 receptors explaining the ubiquitous distribution, and the possibility of multisystem involvement by the SARS-CoV-2 virus [<xref ref-type="bibr" rid="CR12">12</xref>]. The spectrum of presentation of COVID-19 ranges from asymptomatic or mild symptoms to severe-critical illness which is categorized as mild, severe, and critical illness [<xref ref-type="bibr" rid="CR13">13</xref>]. Patients with mild presentation have symptoms of fever, cough, nasal congestion, sore throat, malaise, headache, and myalgia without dyspnea. The severe presentation includes patients with respiratory distress as indicated by a respiratory rate of&#x02009;&#x02265;&#x02009;30/min, SpO<sub>2</sub> (blood oxygen saturation) of&#x02009;&#x02264;&#x02009;93%, PaO<sub>2</sub> (partial pressure of oxygen)/FiO<sub>2</sub> (fraction of inspired oxygen) ratio of&#x02009;&#x0003c;&#x02009;300, or presence of infiltrates in more than half of the lung fields in a radiograph or CT scan. Critical illness encompasses respiratory failure, septic shock, disseminated intravascular coagulation (DIC), and multiorgan dysfunction syndrome [<xref ref-type="bibr" rid="CR13">13</xref>]. Besides respiratory symptoms, multiple cohorts have reported anosmia and dysgeusia, ranging from 34&#x02013;87% of the patients [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Gastrointestinal manifestations, including nausea, vomiting, and diarrhea have been reported in 11&#x02013;24% of the cases and as presenting symptoms in a few reports of COVID-19 [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. In a case series from China, 32% of the patients had ophthalmological manifestations, mainly conjunctival redness and edema with increased eye discharge [<xref ref-type="bibr" rid="CR18">18</xref>]. The other musculoskeletal, dermatological, neurological, and cardiovascular manifestations have been discussed in detail further in this review. The risk factors for severe disease and mortality include old age, immunocompromised status, and comorbidities, such as hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disorders, chronic kidney disease, liver diseases, cancer, and severe obesity [<xref ref-type="bibr" rid="CR19">19</xref>]. Initial data from the COVID-19 Global Rheumatology Alliance provider registry suggests that the features and prognosis in patients with RMDs on immunosuppressive agents contracting SARS-CoV-2 are similar to those in the general population [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec4"><title>Spectrum of rheumatic musculoskeletal manifestations of SARS-CoV-2 infection and antiviral drugs</title><p id="Par64">With scientific literature pouring in from different parts of the world on the clinical presentations and complications of SARS-CoV-2 infections, atypical clinical and laboratory manifestations mimicking RMDs have been reported (Table <xref rid="Tab1" ref-type="table">1</xref>). Musculoskeletal manifestations reported with COVID-19 include arthralgia, myalgia, and proximal weakness with elevated creatine kinase (CK) level [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Some of these manifestations preceded respiratory symptoms of COVID-19. For instance, a patient who presented with proximal weakness with muscle edema on magnetic resonance imaging (MRI), turned negative for myositis-specific and associated antibodies but progressed to develop the symptoms of COVID-19 [<xref ref-type="bibr" rid="CR22">22</xref>]. The spectrum of dermatological manifestations mimicking RMDs includes COVID toes/pseudo-chilblain, transient urticarial or maculopapular rash, livedoid/necrotic lesions, punctiform or diffuse purpura, and erythema elevatum diutinum-like rash [<xref ref-type="bibr" rid="CR23">23</xref>]. COVID toes/pseudo-chilblain is reported predominantly in children and young adults and seems to be a relatively late feature of COVID-19. On the other hand, livedoid/necrotic lesions are seen in elderly patients with severe COVID-19 with no association with the duration of infection. Cases of young stroke involving large vessels, commonly evaluated in rheumatology clinics, have also been reported with COVID-19 [<xref ref-type="bibr" rid="CR24">24</xref>]. A couple of cases of Guillain-Barr&#x000e9; syndrome (GBS) has been described as a consequence of post-viral autoimmune phenomenon. Out of the two reported cases, one succumbed to respiratory complications, and the other recovered with intravenous immunoglobulin (IVIg)/plasmapheresis [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Myocarditis related to COVID-19 in young patients without any prior cardiac morbidity has been reported with early onset of cardiac symptoms. They present with intact coronaries in cardiac echo and MRI showing the classical features of myocarditis. Improvement of myocarditis was noticed following treatment with hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. An increase in the incidence of Kawasaki disease has been reported from Italy as a post-SARS-CoV-2 phenomenon. As compared to the classical Kawasaki disease, these children were older (mean age, 7.5&#x000a0;years) and reported to have more cardiac involvement, shock syndrome, and macrophage activation syndrome (MAS) [<xref ref-type="bibr" rid="CR4">4</xref>]. Cytokine storm or secondary hemophagocytic lymphohistiocytosis (sHLH), yet another entity encountered in rheumatology practice, is reported with COVID-19. The clinical manifestations start 8&#x02013;9&#x000a0;days after the onset of respiratory symptoms and range from unremitting fever, cytopenia, to hyperferritinemia ultimately resulting in multiorgan failure. Hyperferritinemia and elevated serum interleukin (IL)-6 are often associated with mortality in these patients [<xref ref-type="bibr" rid="CR27">27</xref>]. There are reports of improvement with therapy targeting IL-1 and IL-6, and there are multiple ongoing clinical trials to evaluate the role of immunosuppressive therapy for this cytokine storm reported with COVID-19. In addition to these clinical manifestations mimicking RMDs, laboratory reports of positive antinuclear antibodies (ANA) [<xref ref-type="bibr" rid="CR28">28</xref>], antiphospholipid antibodies, lupus anti-coagulant assay [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>] and increased level of D-dimer [<xref ref-type="bibr" rid="CR31">31</xref>] have been reported with COVID-19. All these reports of COVID-19 mimicking or precipitating RMDs points towards a possibility of persisting intermediate to long-term immune dysregulation.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Rheumatic musculoskeletal manifestations associated with SARS-CoV-2 infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Reported with SARS-CoV-2</th><th align="left">Clinical characteristics</th><th align="left">Refs.</th></tr></thead><tbody><tr><td align="left" colspan="4">Musculoskeletal manifestations</td></tr><tr><td align="left">&#x000a0;Arthralgia-Myalgia</td><td align="left">In 14.4&#x02013;44% of the cases</td><td align="left"><p>Early and transient features</p><p>Resolves in 10&#x02013;15&#x000a0;days</p></td><td align="left">[<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">&#x000a0;Acute Myositis</td><td align="left">Case report</td><td align="left"><p>Symptom of myalgia and proximal muscle weakness preceded respiratory symptom of COVID-19</p><p>Elevate Creatine kinase (CK) level (25,384&#x000a0;IU/L)</p><p>MRI showed muscle edema</p><p>Negative MSA and MAAs</p></td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left" colspan="4">Dermatological manifestations</td></tr><tr><td align="left">&#x000a0;COVID toes/pseudo-chilblain</td><td align="left">In&#x02009;~&#x02009;19&#x02013;59% of the pediatric and young adults</td><td align="left"><p>Asymmetrical multiple red&#x02013;purple pustular or vesicular lesions at distal extremities</p><p>Relatively late feature</p></td><td align="left" rowspan="5">[<xref ref-type="bibr" rid="CR23">23</xref>]</td></tr><tr><td align="left">&#x000a0;Skin rash</td><td align="left">In&#x02009;~&#x02009;19% of the cases</td><td align="left"><p>Transient (6&#x02013;9&#x000a0;days) urticarial or maculopapular rash</p><p>Associated with severe disease</p></td></tr><tr><td align="left">&#x000a0;Purpura</td><td align="left">Rare</td><td align="left">Punctiform or diffuse</td></tr><tr><td align="left">&#x000a0;Livedoid/necrotic lesions</td><td align="left">In 6% of the elderly with severe disease</td><td align="left">Acral and truncal distribution with ischemic features in severe cases</td></tr><tr><td align="left">&#x000a0;Erythema elevatum diutinum-like rash</td><td align="left">Rare</td><td align="left">Multiple red&#x02013;purple papulo-nodular lesion over the dorsum of hands</td></tr><tr><td align="left" colspan="4">Neurological manifestations</td></tr><tr><td align="left">&#x000a0;Large vessel stroke in young patients</td><td align="left">Case reports</td><td align="left"><p>National Institute of Health Stroke Score range: 13&#x02013;23</p><p>Probably secondary to endothelitis and coagulopathy secondary to COVID-19</p></td><td align="left">[<xref ref-type="bibr" rid="CR24">24</xref>]</td></tr><tr><td align="left" colspan="4">Cardiovascular manifestations</td></tr><tr><td align="left">&#x000a0;Myocarditis in absence of previous comorbidities</td><td align="left">Case reports</td><td align="left"><p>Likely to occur within 7&#x000a0;days of symptoms</p><p>Circumferential pericardial effusion, global hypokinesia, low ejection fraction and normal cardiac valves on echocardiography</p><p>Normal coronary angiography</p><p>Cardiac MRI: myocardial edema and pattern of late gadolinium-enhancement fulfilling Lake Louis criteria of acute myocarditis</p><p>Improved with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone</p></td><td align="left">[<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td align="left" colspan="4">Multisystem autoinflammatory syndrome</td></tr><tr><td align="left">&#x000a0;Cytokine storm/Secondary Hemophagocytic lymphohistiocytosis (sHLH)</td><td align="left">Represents critical patients with SARS-CoV-2 infection</td><td align="left"><p>After 8&#x02013;9&#x000a0;days of the symptom onset</p><p>Unremitting fever, cytopenia, and hyperferritinemia</p><p>Acute respiratory distress syndrome and multiple organ failure</p><p>Interplay of Interferons, interleukins, chemokines, colony-stimulating factors, and TNF-alpha</p><p>Hyperferritinemia and elevated serum IL-6, associated with mortality</p><p>H-score of&#x02009;&#x0003e;&#x02009;169, 93% sensitivity and 86% specificity for the diagnosis of the sHLH</p><p>Report on improvement with IL-1 and IL-6 inhibitor</p></td><td align="left">[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left" colspan="4">Post-viral autoimmunity</td></tr><tr><td align="left">&#x000a0;Guillain-Barr&#x000e9; syndrome (GBS)</td><td align="left">Case reports</td><td align="left"><p>The interval from COVID symptoms to GBS symptoms was 5&#x02013;10&#x000a0;days</p><p>Axonal or demyelinating variant</p><p>Negative PCR for SARS-CoV-2 from CSF</p><p>One of the patients succumbed to respiratory complications, and the other recovered with IVIg/plasmapheresis</p></td><td align="left">[<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]</td></tr><tr><td align="left">&#x000a0;Kawasaki-like disease</td><td align="left">30-fold increased incidence as compared to the pre-COVID time in Italy</td><td align="left"><p>Higher mean age (7.5&#x000a0;years)</p><p>More cardiac involvement, shock syndrome, and macrophage activation syndrome as compared to pre-COVID-19 Kawasaki disease</p></td><td align="left">[<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td align="left" colspan="4">Laboratory findings</td></tr><tr><td align="left">&#x000a0;Positive Antinuclear antibodies (ANA)</td><td align="left">Reported in 35% of the patients</td><td align="left" rowspan="2"><p>Single-center report</p><p>No impact on outcome with positive ANA</p></td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left">&#x000a0;Anti-Ro52</td><td align="left">Reported in 4.4% of the patients</td></tr><tr><td align="left">&#x000a0;Antiphospholipid antibodies</td><td align="left"><p>Case series (<italic>n</italic>&#x02009;=&#x02009;56)</p><p>LAC positive (<italic>n</italic>&#x02009;=&#x02009;25)</p><p>Anticardiolipin or anti-&#x003b2;2-glycoprotein I antibodies IgG/IgM (<italic>n</italic>&#x02009;=&#x02009;5)</p><p>Case reports (<italic>n</italic>&#x02009;=&#x02009;3)</p><p>Anticardiolipin or anti-&#x003b2;2-glycoprotein I antibodies IgA</p></td><td align="left"><p>Epiphenomenon rather than autoimmunity</p><p>Expert opinion favoring to start heparin in patients with antiphospholipid test positivity</p></td><td align="left">[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left">&#x000a0;Increased <sc>d</sc>-Dimer without DIC</td><td align="left">&#x0003e;&#x02009;0.5&#x000a0;mg/L in 46% of the patients</td><td align="left"><p>Higher chance for ICU admission</p><p>&#x0003e;&#x02009;1&#x000a0;mg/L on admission has 18-times increased mortality (95% CI, 2&#x000b7;6&#x02013;128&#x000b7;6; <italic>p</italic>&#x02009;=&#x02009;0&#x000b7;0033)</p></td><td align="left">[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>COVID-19</italic> coronavirus disease-2019, <italic>CSF</italic> cerebrospinal fluid, <italic>DIC</italic> disseminated intravascular coagulation, <italic>IL</italic> interleukin, <italic>LAC</italic> lupus anti-coagulant, <italic>MAA</italic> myositis-associated autoantibodies, <italic>MSA </italic>myositis-specific autoantibodies, <italic>RA</italic> rheumatoid arthritis, <italic>PCR</italic> polymerase chain reaction, <italic>SARS-CoV-2</italic> severe acute respiratory syndrome coronavirus-2</p></table-wrap-foot></table-wrap></p><p id="Par65">Based on evidence from in-vitro studies and experience from other viral infections, several antiviral therapies are currently in trial/practice in different parts of the world [<xref ref-type="bibr" rid="CR32">32</xref>]. There are reports of rheumatic musculoskeletal adverse reactions following the use of these drugs. Table <xref rid="Tab2" ref-type="table">2</xref> depicts the list of the major anti-SARS-CoV-2 drugs with their mechanisms of action and the important rheumatological adverse events. Of these, some adverse events deserve special mention. Myopathy and neuromyopathy can rarely occur following long-term treatment with chloroquine and hydroxychloroquine [<xref ref-type="bibr" rid="CR33">33</xref>]. Favipiravir can lead to hyperuricemia [<xref ref-type="bibr" rid="CR34">34</xref>]. Lopinavir-ritonavir-related rheumatic adverse events include arthralgia, back pain, osteonecrosis, and vasculitis [<xref ref-type="bibr" rid="CR35">35</xref>]. Ribavirin can cause arthralgia, back pain, myositis, and exacerbation of sarcoidosis [<xref ref-type="bibr" rid="CR36">36</xref>]. Musculoskeletal pain and myalgia have been reported in up to half of the patients on interferon therapy. Additionally, in rare cases, interferon therapy can lead to drug-induced RMDS, such as rheumatoid arthritis, lupus, Sjogren syndrome, myositis, sarcoidosis, and vasculitis [<xref ref-type="bibr" rid="CR37">37</xref>]. With the increased use of these drugs, there is a possibility of a rise in these adverse drug reactions necessitating active pharmacovigilance. Moreover, it must be noted that some of the frontrunner drugs like remdesivir have limited clinical data making it even more important to be vigilant.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Anti-SARS-CoV-2 drugs and its rheumatic musculoskeletal adverse effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Drugs</th><th align="left">Antiviral mechanisms</th><th align="left">Rheumatic musculoskeletal adverse events</th><th align="left">Refs.</th></tr></thead><tbody><tr><td align="left">Chloroquine and hydroxychloroquine</td><td align="left">Inhibit pH-dependent internalization and fusion of the virus with lysosomes</td><td align="left">Myopathy and neuromyopathy</td><td align="left">[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left">Favipiravir</td><td align="left" rowspan="3">Inhibit viral&#x000a0;RNA-dependent RNA polymerase</td><td align="left">Hyperuricemia</td><td align="left">[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left">Remdesivir</td><td align="left">Not reported</td><td align="left"/></tr><tr><td align="left">EIDD-2801</td><td align="left">Not reported</td><td align="left"/></tr><tr><td align="left">Lopinavir-ritonavir</td><td align="left">Protease inhibitor</td><td align="left">Hyperuricemia (&#x02264;&#x02009;5%), musculoskeletal pain (6%), arthralgia (&#x0003c;&#x02009;2%), osteonecrosis, vasculitis, SJS-TEN</td><td align="left">[<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left">Umifenovir</td><td align="left">Block the virus-cell membrane fusion as well as virus-endosome fusion</td><td align="left">Not reported</td><td align="left"/></tr><tr><td align="left">Galidesivir</td><td align="left">Antiviral adenosine nucleoside analog</td><td align="left">Not reported</td><td align="left"/></tr><tr><td align="left">Ribavirin</td><td align="left">Interfere with polymerases, RNA capping, and inosine monophosphate dehydrogenase</td><td align="left"><p>Arthralgia (&#x0003e;&#x02009;10%), musculoskeletal pain (&#x0003e;&#x02009;10%), backache (1&#x02013;10%),</p><p>gout (&#x0003c;&#x02009;1%), myositis (&#x0003c;&#x02009;1%),</p><p>Exacerbation of sarcoidosis (higher incidence in combination with interferon &#x003b1;)</p></td><td align="left">[<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td align="left">Camostat mesylate</td><td align="left">Serine protease inhibitor</td><td align="left">Not reported</td><td align="left"/></tr><tr><td align="left">Interferon &#x003b1; and &#x003b2;</td><td align="left" rowspan="2">Inhibit replication</td><td align="left"><p>Interferon &#x003b1;2b:</p><p>Myalgia (16&#x02013;75%), musculoskeletal pain (1&#x02013;21%), arthralgia (3&#x02013;19%), backache (1&#x02013;19%), amyotrophy (&#x0003c;&#x02009;5%),</p><p>Arthritis (&#x0003c;&#x02009;5%) including RA,</p><p>Other autoimmune disease (&#x0003c;&#x02009;1%) including sarcoidosis, myositis, rhabdomyolysis, SJS, SLE, vasculitis</p><p>Interferon &#x003b2;1a and &#x003b2;1b:</p><p>Myalgia (25&#x02013;29%),</p><p>Backache (23&#x02013;25%),</p><p>Autoimmune hepatitis,</p><p>Immune thrombocytopenia, SLE, osteonecrosis, Sjogren syndrome</p></td><td align="left">[<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr><td align="left">Convalescent plasma</td><td align="left"><p>Chance of transfusion-related adverse events: urticaria, anaphylaxis, transfusion-related acute lung injury</p><p>Latent risk of hyperimmune attacks:</p><p>Possibly via antibody-dependent enhancement of tissue damage and blunting of endogenous immunity to the virus</p></td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>RNA</italic> ribonucleic acid, <italic>SJS-TEN</italic> Steven Johnson syndrome-toxic epidermal necrolysis, <italic>SLE</italic> systemic lupus erythematosus</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec5"><title>Coagulopathy as a consequence of inflammation COVID-19 cases</title><p id="Par66">One of the factors leading to mortality in COVID-19 patients is the presence of coagulopathy [<xref ref-type="bibr" rid="CR38">38</xref>]. The autopsy findings of COVID-19 death from a majority of the cases show the presence of coagulopathy either in the form of deep venous thrombosis, pulmonary embolism, or multiple pulmonary thrombi coexisting with acute respiratory distress syndrome (ARDS) changes in the lungs [<xref ref-type="bibr" rid="CR39">39</xref>]. The laboratory markers of COVID-19 coagulopathy include increased D-dimer level, borderline thrombocytopenia, and prolonged prothrombin time [<xref ref-type="bibr" rid="CR40">40</xref>]. Though the exact mechanism underlying coagulopathy is unclear, a possibility of local lung-TMA as a coronavirus-associated hemostatic lung abnormality (CAHA) is proposed, linking inflammation and endothelial cell activation [<xref ref-type="bibr" rid="CR41">41</xref>]. Endothelial cell activation results in the production of von Willebrand factor (vWF) in excess to the clearance capacity of ADAMTS-13. This leads to local thrombotic microangiopathy and perpetuates lung damage [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par67">The association of netosis has also been proposed with coagulopathy in COVID-19 patients requiring further therapeutic exploration [<xref ref-type="bibr" rid="CR43">43</xref>]. Moreover, the presence of lupus anti-coagulant and antiphospholipid antibodies may point towards the autoimmune contribution rather than just an epiphenomenon. Thus, linking inflammation to coagulopathy which is not a common occurrence in other viral infections suggests the role of immune activation at the vessel wall. This phenomenon warrants serious consideration of the anecdotal evidence supporting the role of immunosuppressants in addition to anticoagulants in severe COVID-19 cases [<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec6"><title>SARS-CoV-2 infection and autoimmunity</title><p id="Par68">The interplay of various genetic, hormonal, immunological, and environmental factors constitutes the mosaic of autoimmunity [<xref ref-type="bibr" rid="CR45">45</xref>]. Viral infections play a substantial role in the development of several autoimmune diseases in individuals with underlying immune dysregulation [<xref ref-type="bibr" rid="CR46">46</xref>]. Follow up data from survivors of viral outbreaks like influenza, Zika, Ebola, and Chikungunya have shown development of autoimmune phenomenon within weeks to months after recovery. While GBS, fulminant type1 diabetes, IgA vasculitis, APS have been observed after a previous outbreak of influenza [<xref ref-type="bibr" rid="CR47">47</xref>], transverse myelitis, arthralgia, myalgia, and arthritis were reported following Zika [<xref ref-type="bibr" rid="CR48">48</xref>], Chikungunya [<xref ref-type="bibr" rid="CR49">49</xref>] and Ebola infections [<xref ref-type="bibr" rid="CR50">50</xref>]. Besides overt clinical manifestations, long-term persistence of autoreactive cells and autoantibodies (against antiphospholipid with influenza and ds-DNA and heat shock protein-60 with Ebolavirus) have also been demonstrated with some of these infections [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The mechanisms by which viruses disrupt self-tolerance include molecular mimicry, epitope spreading, bystander activation, persistence of the latent virus, and poly/oligoclonal immune activation in the background of autoimmunity mosaic [<xref ref-type="bibr" rid="CR51">51</xref>]. Table <xref rid="Tab3" ref-type="table">3</xref> enlists known viral infections and associated autoimmune diseases with the possible mechanisms as elaborately described by Smatti et al. [<xref ref-type="bibr" rid="CR52">52</xref>]. Similar mechanisms may lead to autoimmunity following SARS-CoV-2 infection. We herein describe some of the possible mechanism of autoimmunity following SARS-CoV-2 infection as follows:<table-wrap id="Tab3"><label>Table 3</label><caption><p>Mechanisms of autoimmune manifestation following different viral infections</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Molecular mechanisms</th><th align="left">Viruses</th><th align="left">Autoimmune diseases</th></tr></thead><tbody><tr><td align="left" rowspan="17">Molecular mimicry</td><td align="left">Coxsackievirus</td><td align="left">Type 1 diabetes mellitus</td></tr><tr><td align="left">Cytomegalovirus</td><td align="left">Multiple sclerosis, type 1 diabetes mellitus, anti-&#x003b2;2 glycoprotein-1 antibody</td></tr><tr><td align="left">Enterovirus</td><td align="left">Type 1 diabetes mellitus</td></tr><tr><td align="left">Epstein-Barr virus</td><td align="left">Grave&#x02019;s disease, Hashimoto&#x02019;s disease, multiple sclerosis</td></tr><tr><td align="left">Hepatitis C virus</td><td align="left">Immune thrombocytopenia, autoimmune hepatitis, polyarthritis</td></tr><tr><td align="left">Herpes simplex virus</td><td align="left">Human herpes encephalitis</td></tr><tr><td align="left">Human T-lymphotropic virus-1</td><td align="left">Myelopathy/tropical spastic paraparesis</td></tr><tr><td align="left">Influenza</td><td align="left">Acute disseminated encephalomyelitis</td></tr><tr><td align="left">Measles virus</td><td align="left">Multiple sclerosis</td></tr><tr><td align="left">Theiler&#x02019;s virus</td><td align="left">Multiple sclerosis</td></tr><tr><td align="left">Varicella-Zoster virus</td><td align="left">Multiple sclerosis</td></tr><tr><td align="left">West Nile virus</td><td align="left">Myasthenia gravis</td></tr><tr><td align="left">Zika virus</td><td align="left">Guillain-Barr&#x000e9; syndrome</td></tr><tr><td align="left">Chikungunya virus</td><td align="left">Symmetric polyarthritis</td></tr><tr><td align="left">Cytomegalovirus</td><td align="left">Rheumatoid arthritis, SLE</td></tr><tr><td align="left">Epstein-Barr virus</td><td align="left">Rheumatoid arthritis</td></tr><tr><td align="left">Hepatitis C virus</td><td align="left">SLE, porphyria cutanea tarda</td></tr><tr><td align="left" rowspan="6">Bystander effect</td><td align="left">Hepatitis C virus</td><td align="left">Vasculitis, cryoglobulinemia, Sjogren Syndrome, thrombocytopenia</td></tr><tr><td align="left">Enteroviruses</td><td align="left">Type 1 diabetes mellitus</td></tr><tr><td align="left">Herpes simplex virus</td><td align="left">Stromal keratitis</td></tr><tr><td align="left">Human Herpesvirus 6A</td><td align="left">Thyroiditis</td></tr><tr><td align="left">Human immunodeficiency virus</td><td align="left">Autoantibodies in AIDS</td></tr><tr><td align="left">Influenza</td><td align="left">Acute disseminated encephalomyelitis</td></tr><tr><td align="left" rowspan="2">Persistent infection and polyclonal activation</td><td align="left">Epstein-Barr virus</td><td align="left">Lymphoproliferation</td></tr><tr><td align="left">Hepatitis C virus</td><td align="left">Mixed cryoglobulinemia</td></tr></tbody></table><table-wrap-foot><p><italic>AIDS</italic> acquired immunodeficiency syndrome, <italic>SLE</italic> systemic lupus erythematosus</p></table-wrap-foot></table-wrap></p><sec id="Sec7"><title>Molecular mimicry</title><p id="Par69">Molecular mimicry, as a result of the cross-reacting epitope between the virus and the host, leads to both humoral and cellular autoreactivity (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a) [<xref ref-type="bibr" rid="CR53">53</xref>]. This mechanism plays a vital role in the pathogenesis of prototype systemic rheumatological diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and Sjogren syndrome [<xref ref-type="bibr" rid="CR54">54</xref>]. SARS-CoV-2 proteins displayed at least one match with the human protein on a comparative peptidome analysis comprising of 37 viral proteins [<xref ref-type="bibr" rid="CR55">55</xref>]. These similarities potentially can lead to loss of tolerance to self-peptides and result in autoimmunity. Recently, an epitope mapping analysis has identified immunogenic linear epitopes, 2&#x02032;-O-ribose methyltransferase, RNA-dependent RNA polymerase and 3&#x02032;-to-5&#x02032; exonuclease proteins from autoimmune dermatomyositis patients matching with the SARS-CoV-2 peptides [<xref ref-type="bibr" rid="CR56">56</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Mechanism of autoimmunity through molecular mimicry and bystander activation of antigen-presenting cells and proinflammation. <bold>a</bold> Molecular mimicry: The processing of cross-reactive peptide and presentation via MHC1 and MHC2 to T cells lead to the generation of autoreactive cells. <italic>ACE2</italic> angiotensin-converting enzyme 2, <italic>ER</italic> endoplasmic reticulum, <italic>ERAP</italic> endoplasmic reticulum aminopeptidase, <italic>MHC</italic> major histocompatibility. <bold>b</bold> Bystander activation of antigen-presenting cells and proinflammation: The cytoplasmic pattern recognition receptors after identifying viral RNA phosphorylates downstream IRF-3, IRF-7, and NF&#x003ba;B leading to the secretion of interferons as well as proinflammatory cytokines. <italic>CCL2</italic> chemokine (C&#x02013;C motif) ligand 2, <italic>CXCL8</italic> C-X-C motif chemokine ligand 8, <italic>IL</italic> interleukin, <italic>IRF</italic> interferon regulatory transcription factor, <italic>ISRE</italic> interferon-stimulated response element, <italic>MDA-5</italic> melanoma differentiation-associated protein-5, <italic>MVAS</italic> mitochondrial&#x000a0;antiviral-signaling protein, <italic>MYD88</italic> myeloid differentiation primary response-88, <italic>RIG-1</italic> retinoic acid-inducible gene-I, <italic>NF-&#x003ba;B</italic> nuclear factor kappa-light-chain-enhancer of activated B cells), <italic>TLR</italic> toll-like receptor, <italic>TNF</italic> tumor necrosis factor</p></caption><graphic xlink:href="296_2020_4639_Fig1_HTML" id="MO1"/></fig></p><p id="Par70">In addition to the presence of cross-reactive epitopes, activation of antigen-presenting cells (APCs) either by an adjuvant or infectious stimulus is essential to increase the expression of co-receptors [<xref ref-type="bibr" rid="CR51">51</xref>]. Viral RNA of the SARS-CoV-2 activates dendritic cells through cytosolic RIG like receptors and endosomal TLRs, as well as by the release of interferon &#x003b1;/&#x003b2; and &#x003b3; enhancing antigen-presenting capacity (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b) [<xref ref-type="bibr" rid="CR57">57</xref>]. Such activation by the virus can result in precipitation of inflammatory cascade in the presence of an already existing cross-reactive antigen. The clinical phenomenon of initial asymptomatic to mild symptoms followed by severe autoinflammatory syndrome in COVID-19 is proposed to be due to a similar autoreactive adaptive response with SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par71">The role of genetic susceptibility should also be considered while evaluating the role of cross-reactive epitopes in precipitating autoimmunity. Human leukocyte antigen (HLA) susceptibility map for SARS-CoV-2 has shown that HLA-B*15:03 efficiently presents highly conserved SARS-CoV-2 peptides that are shared among the common human coronaviruses [<xref ref-type="bibr" rid="CR58">58</xref>]. The association of HLA-B*15 with primary Sjogren&#x02019;s syndrome [<xref ref-type="bibr" rid="CR59">59</xref>] and Bechet&#x02019;s diseases [<xref ref-type="bibr" rid="CR60">60</xref>] is well documented, and the consequence of its association with SARS-CoV-2 peptide presentation needs to be carefully followed up.</p><p id="Par72">Following molecular mimicry with the dominant epitope, diversification in epitope specificity commences resulting in the neo-epitopes presentation. Immune response to these neo-epitopes differs from that to the dominant epitope and involves newer targets for autoimmunity [<xref ref-type="bibr" rid="CR61">61</xref>]. The sequential appearance of various autoantibodies in RA and SLE follows the theory of epitope spreading [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. In SLE, before clinical disease onset, autoantibodies are targeted against Ro, La, and phospholipid antigens. In contrast, the clinical manifestations commence with the appearance of autoantibodies to ds-DNA, Smith (Sm), and ribonuclear protein (RNP) antigens [<xref ref-type="bibr" rid="CR64">64</xref>]. Although with SARS-CoV-2 infection, epitope diversification is not reported, it would be worthwhile to closely follow those patients with positive autoantibodies.</p></sec><sec id="Sec8"><title>Bystander activation and damage</title><p id="Par73">Pre-clinical studies of diabetes and experimental autoimmune encephalomyelitis suggest the role of bystander activation as one of the mechanisms predisposing to autoimmunity [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. The bystander damage starts with the virus-specific CD8<sup>+</sup> T cells migrating to the infected target tissues and exerting perforin and granzyme-mediated cytotoxicity. The target cell death in the inflammatory milieu activates the surrounding macrophages to release reactive oxygen species and nitric oxide resulting in bystander killing of surrounding uninfected cells [<xref ref-type="bibr" rid="CR67">67</xref>]. The CD4<sup>+</sup> T cells contribute to this bystander damage through the release of proinflammatory cytokines and enhancing phagocytic activities of macrophage [<xref ref-type="bibr" rid="CR68">68</xref>]. Ineffective clearance of these killed cells exposes autoantigen to antigen-presenting cells, resulting in the generation of autoreactive cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR51">51</xref>]. The association of hepatitis C virus and Sjogren syndrome serves a classical example among RMDs explaining the bystander activation and damage theory [<xref ref-type="bibr" rid="CR69">69</xref>]. Hepatitis C, primarily a hepatotropic virus, also exhibits sialotropism and lymphotropism leading to bystander activation of the salivary gland epithelium and lymphocytes, respectively [<xref ref-type="bibr" rid="CR70">70</xref>]. The activation of salivary epithelial cells and resultant antiviral defense in the salivary gland result in bystander damage manifesting as sicca symptoms and parotidomegaly. Bystander activation and dysregulated proliferation of the lymphocytes result in cryoglobulinemic vasculitis, generation of rheumatoid factor, autoantibodies (ANA, anti-SSA, anti-SSB), and low complements.<fig id="Fig2"><label>Fig. 2</label><caption><p>Bystander killing: virus-specific CD8<sup>+</sup> T cells migrating to the infected target tissues and exerting perforin and granzyme-mediated cytotoxicity. The CD4<sup>+</sup> T cells contribute to this bystander killing by the release of proinflammatory cytokines and enhancing phagocytic activities of the macrophages. The free oxygen radicals and cytokines secreted from the activated macrophages result in bystander killing off the surrounding non-infected cells. Ineffective clearance of these killed cells exposes autoantigen to the antigen-presenting cells, resulting in the generation of autoreactive cells in the presence of the costimulatory molecules</p></caption><graphic xlink:href="296_2020_4639_Fig2_HTML" id="MO2"/></fig></p><p id="Par74">Lymphopenia due to reduced CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells is well documented in severe cases of SARS-CoV-2. The reduction is possibly secondary to functional exhaustion and preferential accumulation of the primed lymphocytes at the site of viral infection [<xref ref-type="bibr" rid="CR71">71</xref>]. These preferentially accumulated lymphocytes exhibit increased activity as confirmed by the expression of HLA-DR, CD69, CD38, and CD44. Activated lymphocytes, along with activated macrophages at the target tissue lead to bystander killing of adjacent, non-infected healthy cells via proinflammatory cytokine and reactive oxygen species [<xref ref-type="bibr" rid="CR72">72</xref>]. With SARS-CoV-2 infection, the multisystem inflammatory syndrome appears after the peak of viral load. This suggests a build-up of inflammatory cytokine and bystander activation of the macrophages by SARS-CoV-2 through pattern recognition receptors (PRR). It also suggests bystander killing of the cells devoid of ACE2 receptors by free oxygen radicals released in the inflammatory milieu [<xref ref-type="bibr" rid="CR73">73</xref>]. Bystander damage can be one of the mechanisms responsible for the manifestations like ARDS, myocarditis, and neurological involvement reported with SARS-CoV-2 infection. Autopsy reports of COVID-19 patients show diffuse infiltration of lymphocytes in the lungs and focal infiltration in the heart, kidney, liver, pancreas, and adrenal gland, suggesting bystander damage by cytotoxic CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR74">74</xref>]. Besides, in patients surviving SARS-CoV-2 infection, bystander activation may lead to sequestered autoantigen presentation leading to the emergence of neoepitope and autoimmune manifestations, as seen in SLE [<xref ref-type="bibr" rid="CR75">75</xref>].</p></sec><sec id="Sec9"><title>Persistent immune activation</title><p id="Par75">The third theory of persistent viral infection and oligo/polyclonal activation can be explained by the constant presence of viral antigens driving immune-proliferation resulting from the ineffective clearance of viruses [<xref ref-type="bibr" rid="CR76">76</xref>]. Such mechanisms are commonly encountered with the Epstein-Barr virus which resides in autoreactive B cells imparting immortality to the cells. These long-living autoreactive B cells cause lymphoproliferation and polyclonal activation culminating in chronic autoimmunity [<xref ref-type="bibr" rid="CR77">77</xref>]. As the possibility of the persistence of the SARS-CoV-2 virus cannot be completely ruled out, this may add to an additional mechanism of autoimmunity. On a brighter side, complete clearance is reported in cases of other members of the coronavirus family following the development of specific antibodies [<xref ref-type="bibr" rid="CR78">78</xref>], making the possibility of persistent immune activation due to SARS-CoV-2 chronicity less likely.</p></sec><sec id="Sec10"><title>Netosis</title><p id="Par76">Knight et al. noted the formation of neutrophil extracellular traps (NETs) by demonstrating elevated serum levels of cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3 among patients with COVID-19 compared to healthy controls [<xref ref-type="bibr" rid="CR79">79</xref>]. NETs consist of extracellular webs of nuclear chromatin materials and supporting histones along with antibacterial proteins and oxidant enzymes from neutrophilic granules. The principal role of this transient phenomenon is to trap the microorganisms to resolve the infection. However, sustained netosis may beget inflammation and thrombosis [<xref ref-type="bibr" rid="CR80">80</xref>]. In the past decade, researchers have established the role of netosis in autoimmune disease including but not limited to, SLE, RA, anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), antiphospholipid antibody syndrome (APS), and an autoinflammatory syndrome, deficiency of adenosine deaminase-2 (DADA-2) [<xref ref-type="bibr" rid="CR81">81</xref>].</p><p id="Par77">In COVID-19, a rise in neutrophil counts during early infection is a poor prognostic factor. The migration of these neutrophils towards virally infected sites follows the IL-8 gradient [<xref ref-type="bibr" rid="CR82">82</xref>]. The production of free oxygen radicals and IL-1&#x003b2; by macrophages and pyroptosis of virally infected cells stimulate and maintain netosis of the migrated neutrophils [<xref ref-type="bibr" rid="CR83">83</xref>]. Exposure of chromatin, histones, and neutrophil granules with sustained netosis, serve as a source of autoantigens. This may lead to the recognition of self-peptides by antigen-presenting cells and result in the expansion of autoreactive cells (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>NETosis: Neutrophils recruited to the target tissues following chemokine IL-8 gradient gets activated by IL-1&#x003b2; and free oxygen radicals leading to a sustained generation of NETosis. NETs carrying autoantigen, which gets recognized by dendritic cells, leads to the activation of autoreactive T cells. <italic>IL</italic> interleukin, <italic>NET</italic> neutrophil extracellular traps</p></caption><graphic xlink:href="296_2020_4639_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>Population behavioral modification with COVID-19</title><p id="Par78">In addition to the interaction of virus and host, the environmental factors play an important role in susceptibility and protection to autoimmune disease [<xref ref-type="bibr" rid="CR45">45</xref>]. A paradigm shift has taken place in the human behavior with advocacy of social distancing, handwashing, use of mask and gloves, and movement restrictions in an attempt to contain the spread of COVID-19 [<xref ref-type="bibr" rid="CR21">21</xref>]. This shift is a double-edged sword in the mosaic of autoimmunity. The positive side is reflected by a reduction in airborne infectious disease with a documented shortening of the influenza season in the northern hemisphere by about six weeks [<xref ref-type="bibr" rid="CR84">84</xref>]. This may reduce the occurrence of subsequent effects of influenza infection on RMDs. Diseases like acute rheumatic fever, where overcrowding plays an essential role in familial predisposition may also reduce with these hygienic measures [<xref ref-type="bibr" rid="CR85">85</xref>]. At the negative spectrum of these hygienic measures, an increase in autoimmune disease should be born in mind as proposed by the proponents of the hygiene hypothesis. During the second half of the twentieth century, with the improvement in lifestyle especially in the developed world, the burden of infectious disease reduced with a parallel increase in autoimmune diseases like type1 diabetes mellitus, inflammatory bowel disease, and multiple sclerosis [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par79">One of the key influencers to hygiene hypothesis is the microbiome of an individual which plays a protective role against autoimmune diseases. The mechanisms conferring protections by microbiome include antigenic competition, the role of lymphocyte homeostasis against pathogens, and the effect on immune regulatory pathway favoring the anti-inflammatory milieu with IL-10 and TGF-&#x003b2; secretion from the regulatory cells and TLR mediated receptor desensitization [<xref ref-type="bibr" rid="CR87">87</xref>]. Disturbance in this microbiome is evident in the pathogenesis of autoimmune disorders including RA, SLE, and inflammatory bowel disease [<xref ref-type="bibr" rid="CR88">88</xref>]. Over practice of distancing and antimicrobial sanitizers may lead to dysbiosis triggering autoimmunity. Additionally, the psychological stress caused by isolation, the anxiety of contracting the infection, and the economic burden along with its numerous adverse short- and long-term socio-economic consequences can turn as a trigger of various autoimmune diseases [<xref ref-type="bibr" rid="CR89">89</xref>]. In summary, understanding the immune consequences of SARS-Cov-2 interaction with the host along with the environmental changes may explain the basis of rheumatic musculoskeletal manifestations.</p></sec></sec><sec id="Sec12"><title>Preventive therapy against SARS-CoV-2 and the risk of autoimmunity</title><p id="Par80">Currently, a multitude of vaccines for the prevention of SARS-CoV-2 infection is under investigation [<xref ref-type="bibr" rid="CR90">90</xref>]. Except for the nucleocapsid, all immunogenic epitopes have been reported to have at least one match with human proteins [<xref ref-type="bibr" rid="CR55">55</xref>]. This homology between the human and viral proteins is an established factor in vaccine-induced autoimmunity with the mechanism of molecular mimicry, as discussed above. Furthermore, there is a theoretical possibility of the involvement of pathogenic priming in re-infection by COVID-19, triggering the release of proinflammatory cytokines leading to cytokine storm [<xref ref-type="bibr" rid="CR55">55</xref>]. Similar instances have been experienced with H1N1 influenza [<xref ref-type="bibr" rid="CR91">91</xref>], MERS [<xref ref-type="bibr" rid="CR92">92</xref>], and SARS [<xref ref-type="bibr" rid="CR93">93</xref>]. Thus, while developing vaccines, these epitopes should be carefully excluded to minimize unintended autoimmunity due to the risk of pathogenic priming.</p></sec><sec id="Sec13"><title>Targeted immunosuppressive therapy for SARS-CoV-2 infection</title><p id="Par81">The clinical outcome of the patients relies on the fate of interaction between the SARS-CoV-2 virus and immune cells of the host [<xref ref-type="bibr" rid="CR94">94</xref>]. Modulation of this virus-host cell interaction and its aftereffects can be possibly achieved with immunomodulatory therapies repurposed from drugs used in autoimmune diseases. The potential drug targets for COVID-19 has been reviewed extensively by Misra et al. [<xref ref-type="bibr" rid="CR8">8</xref>]. In the early asymptomatic or mild symptomatic stage, antiviral therapy is likely to have maximum efficacy, and the addition of interferon therapy at this stage may theoretically benefit from augmenting the innate antiviral response. In the next stage of pulmonary and systemic hyper-inflammation, early initiation of immunosuppressant, including IVIg, corticosteroids, IL-6, or IL-1 inhibitors may help to halt the immune-mediated damage [<xref ref-type="bibr" rid="CR95">95</xref>]. We have summarized the plausible role of targeted immunosuppressive therapy in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. The role of IL-1 and IL-6 in particular is worth noticing as they are significant drivers of proinflammation in the cytokine release syndrome (CRS) of COVID-19. The IL-1 receptor antagonist, anakinra, has proven its beneficial effects in the MAS in rheumatic diseases, as well as in chimeric antigen receptor T cell (CAR-T)-mediated severe CRS [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>]. Data from uncontrolled or historically controlled case series are encouraging for anakinra showing its safety and benefit on mortality, especially in critically ill patients with COVID-19 [<xref ref-type="bibr" rid="CR98">98</xref>]. The high level of IL-6 in COVID-19 patients results from the secretion through viral infected respiratory cells, as well as from the infiltrating lymphocytes and monocytes [<xref ref-type="bibr" rid="CR99">99</xref>]. The anti-IL-6 treatment strategy has shown efficacy in a similar CRS-like phenomenon observed with MAS in rheumatic diseases and has become an attractive target for COVID-19 critical cases [<xref ref-type="bibr" rid="CR100">100</xref>]. To date, the supporting evidence for the beneficial effects of tocilizumab (a monoclonal antibody against the IL-6 receptor) is limited to observational studies [<xref ref-type="bibr" rid="CR101">101</xref>]. The results of ongoing randomized controlled trials with IL-1 and IL-6 targeted therapy may clarify the role of tocilizumab in COVID-19. The downstream effects of IL-6 and its receptor are mediated via cytosolic Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling, a common pathway for multiple proinflammatory cytokines. Trials with baricitinib, which targets JAK-STAT signaling, are also ongoing in critically ill patients with COVID-19 [<xref ref-type="bibr" rid="CR102">102</xref>].<fig id="Fig4"><label>Fig. 4</label><caption><p>Targeted immunosuppressive therapy for COVID-19: Macrophages play a significant role in cytokine release syndrome associated with SARS-CoV-2 infection. The cells get activated directly by viruses as well as bystander activation with autocrine and paracrine actions of the proinflammatory cytokines mainly derived from the macrophages, NK cells, and T cells. The target of immunosuppressive therapy is denoted by the numbered boxes as described below. The red color box denotes the drugs for which clinical trials are ongoing and the grey color box denotes the drugs for which there is no ongoing clinical trial registered at present for the treatment of COVID-19. (1) TLR7 mediated viral signaling at the endosomal level&#x02014;&#x0003e;&#x02009;chloroquine and hydroxychloroquine. (2) TLR4-TRIF signaling&#x02014;&#x0003e;&#x02009;plausible therapeutic target, no approved drug. (3) IRAK4 inhibitor&#x02014;&#x0003e;&#x02009;PF-06650833, CA-4948. (4) (a) Anti IL-1&#x003b2;&#x02014;&#x0003e;&#x02009;canakinumab, (b) IL-1 receptor antagonist-&#x02009;&#x0003e;&#x02009;anakinra. (5) TNF inhibitors&#x02014;&#x0003e;&#x02009;infliximab, adalimumab, etanercept. (6) GM-CSF signaling inhibition&#x02014;&#x0003e;&#x02009;lenzilumab. (7) (a) Anti IL-6&#x02014;&#x0003e;&#x02009;siltuximab, clazakizumab (b) Anti IL-6 receptor&#x02009;&#x0003e;&#x02009;tocilizumab, sarilumab. (8) Anti IFN &#x003b3;&#x02014;&#x0003e;&#x02009;emapalumab. (9) JAK inhibitor&#x02014;&#x0003e;&#x02009;baricitinib, ruxolitinib, tofacitinib (multi-cytokine targeted therapy). <italic>CCL2</italic> chemokine (C&#x02013;C motif) ligand 2, <italic>CXCL8</italic> C-X-C motif chemokine ligand 8, <italic>ACE2</italic> angiotensin-converting enzyme 2, <italic>GM-CSF</italic> granulocyte&#x02013;macrophage colony-stimulating factor, <italic>IFN</italic> interferon, <italic>IL</italic> interleukin, <italic>IRAK4</italic> interleukin-1 receptor-associated kinase 4, <italic>IRF</italic> interferon regulatory transcription factor, <italic>ISRE</italic> interferon-stimulated response element, <italic>JAK</italic> Janus kinase, <italic>MDA-5</italic> melanoma differentiation-associated protein-5, <italic>MVAS</italic> mitochondrial&#x000a0;antiviral-signaling protein, <italic>MYD88</italic> myeloid differentiation primary response-88, <italic>RIG-1</italic> retinoic acid-inducible gene-I, <italic>NF-&#x003ba;B</italic> nuclear factor kappa-light-chain-enhancer of activated B cells, <italic>STAT</italic> signal transducer and activator of transcription, <italic>TLR</italic> toll-like receptor, <italic>TNF</italic> tumor necrosis factor</p></caption><graphic xlink:href="296_2020_4639_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>Conclusion</title><p id="Par82">In this review, we primarily aimed at understanding the potential pathways and manifestations leading to autoimmunity and other RMD-like illnesses that could be triggered due to COVID-19 or the treatment for the same. This information may help the rheumatology community to tackle the threat of novel RMDs, RMD mimics, and other manifestations, including cytokine storm, Kawasaki disease, and coagulopathy. The immune consequences of SARS-CoV-2-host interaction along with the environmental changes, explain the basis of rheumatic musculoskeletal manifestations of COVID-19. There is a need for preparedness for a possible surge in diverse autoimmune diseases following the pandemic. The rheumatology community is already joining hands to treat, support, and inform our existing patient partners during this pandemic with the advantage of accessibility to cutting edge technology at our disposal. With a likely long-term coexistence of SARS-CoV-2 and the human host and the use of numerous therapeutic strategies, this preparedness may help in the effective management of the rheumatic manifestations of SARS-CoV-2 infection in the post-COVID-19 era.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Sanket Shah and Debashish Danda have contributed equally as first authors.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>SS, VSN, and DD have initially conceptualized the review; SS, CKG, SD, and AMB were involved in drafting and critically revising the review; SS prepared all the figures with inputs from CKG and VSN; VSN and DD have provided expert inputs and updated the final review. All authors have provided substantial contributions to the conception and design of the work along with the interpretation. All authors have substantially contributed in drafting the manuscript and revising it critically for important intellectual content. All authors have approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work related to accuracy and integrity.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funding or support was received for the work.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Conflicts of interest</title><p id="Par83">The authors declare that they have no conflict of interest.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">WHO Coronavirus Disease (COVID-19) Dashboard. <ext-link ext-link-type="uri" xlink:href="https://covid19.who.int/?gclid=Cj0KCQjwwr32BRD4ARIsAAJNf_0jdmZQ1hkz7onImyjahwc-N0H4WTwXnVU7bgQObfk_Vct9yucybbkaAk0oEALw_wcB">https://covid19.who.int/?gclid=Cj0KCQjwwr32BRD4ARIsAAJNf_0jdmZQ1hkz7onImyjahwc-N0H4WTwXnVU7bgQObfk_Vct9yucybbkaAk0oEALw_wcB</ext-link>. Accessed 28 May 2020</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Aziz</surname><given-names>TMA</given-names></name><name><surname>Stockand</surname><given-names>JD</given-names></name></person-group><article-title>Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status</article-title><source>Infect Genet Evol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.meegid.2020.104327</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>MZ</given-names></name><name><surname>Poh</surname><given-names>CM</given-names></name><name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name><name><surname>MacAry</surname><given-names>PA</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name></person-group><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nat Rev Immunol</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id><?supplied-pmid 32346093?><pub-id pub-id-type="pmid">32346093</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verdoni</surname><given-names>L</given-names></name><name><surname>Mazza</surname><given-names>A</given-names></name><name><surname>Gervasoni</surname><given-names>A</given-names></name><etal/></person-group><article-title>An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study</article-title><source>Lancet Lond Engl</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)31103-X</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toscano</surname><given-names>G</given-names></name><name><surname>Palmerini</surname><given-names>F</given-names></name><name><surname>Ravaglia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; Syndrome associated with SARS-CoV-2</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMc2009191</pub-id><?supplied-pmid 32302082?><pub-id pub-id-type="pmid">32302082</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>P</given-names></name><name><surname>Beretta</surname><given-names>S</given-names></name><name><surname>Piatti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Guillain-Barr&#x000e9; syndrome related to COVID-19 infection</article-title><source>Neurol Neuroimmunol Neuroinflammation</source><year>2020</year><volume>7</volume><issue>4</issue><fpage>e741</fpage><pub-id pub-id-type="doi">10.1212/NXI.0000000000000741</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Lancet Rheumatology</collab></person-group><article-title>Unity amidst uncertainty: COVID-19 pandemic fosters collaboration in rheumatology community</article-title><source>Lancet Rheumatol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30082-5</pub-id><?supplied-pmid 32501451?><pub-id pub-id-type="pmid">32501451</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>DP</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Gasparyan</surname><given-names>AY</given-names></name><name><surname>Zimba</surname><given-names>O</given-names></name></person-group><article-title>Rheumatologists&#x02019; perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets</article-title><source>Clin Rheumatol</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s10067-020-05073-9</pub-id><?supplied-pmid 32277367?><pub-id pub-id-type="pmid">32277367</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Brahmer</surname><given-names>JR</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Immune-related adverse events of checkpoint inhibitors</article-title><source>Nat Rev Dis Primer</source><year>2020</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1038/s41572-020-0160-6</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostine</surname><given-names>M</given-names></name><name><surname>Cappelli</surname><given-names>LC</given-names></name><name><surname>Calabrese</surname><given-names>C</given-names></name><etal/></person-group><article-title>Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?</article-title><source>Ann Rheum Dis</source><year>2019</year><volume>78</volume><issue>6</issue><fpage>860</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2018-214748</pub-id><?supplied-pmid 30659050?><pub-id pub-id-type="pmid">30659050</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batlle</surname><given-names>D</given-names></name><name><surname>Wysocki</surname><given-names>J</given-names></name></person-group><article-title>Satchell K (2020) Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?</article-title><source>Clin Sci Lond Engl</source><year>1979</year><volume>134</volume><issue>5</issue><fpage>543</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1042/CS20200163</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>M</given-names></name><name><surname>Lely</surname><given-names>A</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J Pathol</source><year>2004</year><volume>203</volume><issue>2</issue><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/path.1570</pub-id><?supplied-pmid 15141377?><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>McGoogan</surname><given-names>JM</given-names></name></person-group><article-title>Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>13</issue><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacomelli</surname><given-names>A</given-names></name><name><surname>Pezzati</surname><given-names>L</given-names></name><name><surname>Conti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study</article-title><source>Clin Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa330</pub-id><?supplied-pmid 32407467?><pub-id pub-id-type="pmid">32407467</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechien</surname><given-names>JR</given-names></name><name><surname>Chiesa-Estomba</surname><given-names>CM</given-names></name><name><surname>Hans</surname><given-names>S</given-names></name><name><surname>Barillari</surname><given-names>MR</given-names></name><name><surname>Jouffe</surname><given-names>L</given-names></name><name><surname>Saussez</surname><given-names>S</given-names></name></person-group><article-title>Loss of smell and taste in 2013 European patients with mild to moderate COVID-19</article-title><source>Ann Intern Med</source><year>2020</year><pub-id pub-id-type="doi">10.7326/M20-2428</pub-id><?supplied-pmid 32449883?><pub-id pub-id-type="pmid">32449883</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>J-S</given-names></name><name><surname>Hu</surname><given-names>J-H</given-names></name><etal/></person-group><article-title>Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms</article-title><source>Gut</source><year>2020</year><volume>69</volume><issue>6</issue><fpage>1002</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320926</pub-id><?supplied-pmid 32213556?><pub-id pub-id-type="pmid">32213556</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>P</given-names></name><name><surname>Choi</surname><given-names>JJ</given-names></name><name><surname>Pinheiro</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Clinical characteristics of Covid-19 in New York City</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>24</issue><fpage>2372</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2010419</pub-id><?supplied-pmid 32302078?><pub-id pub-id-type="pmid">32302078</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Duan</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province</article-title><source>China JAMA Ophthalmol</source><year>2020</year><volume>138</volume><issue>5</issue><fpage>575</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2020.1291</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">CDC Coronavirus Disease 2019 (COVID-19) Centers for Disease Control and Prevention (2020). <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</ext-link></mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gianfrancesco</surname><given-names>MA</given-names></name><name><surname>Hyrich</surname><given-names>KL</given-names></name><name><surname>Gossec</surname><given-names>L</given-names></name><etal/></person-group><article-title>Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries</article-title><source>Lancet Rheumatol</source><year>2020</year><volume>2</volume><issue>5</issue><fpage>e250</fpage><lpage>e253</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30095-3</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Overview of Public Health and Social Measures in the context of COVID-19. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail-redirect/overview-of-public-health-and-social-measures-in-the-context-of-covid-19">https://www.who.int/publications-detail-redirect/overview-of-public-health-and-social-measures-in-the-context-of-covid-19</ext-link></mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beydon</surname><given-names>M</given-names></name><name><surname>Chevalier</surname><given-names>K</given-names></name><name><surname>Tabaa</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Myositis as a manifestation of SARS-CoV-2</article-title><source>Ann Rheum Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217573</pub-id><?supplied-pmid 32327427?><pub-id pub-id-type="pmid">32327427</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Casas CG, Catal&#x000e0; A, Hern&#x000e1;ndez GC, et al (2020) Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 10.1111/bjd.19163</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxley</surname><given-names>TJ</given-names></name><name><surname>Mocco</surname><given-names>J</given-names></name><name><surname>Majidi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Large-vessel stroke as a presenting feature of Covid-19 in the young</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>20</issue><fpage>e60</fpage><pub-id pub-id-type="doi">10.1056/NEJMc2009787</pub-id><?supplied-pmid 32343504?><pub-id pub-id-type="pmid">32343504</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inciardi</surname><given-names>RM</given-names></name><name><surname>Lupi</surname><given-names>L</given-names></name><name><surname>Zaccone</surname><given-names>G</given-names></name><etal/></person-group><article-title>Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)</article-title><source>JAMA Cardiol</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jamacardio.2020.1096</pub-id><?supplied-pmid 32219357?><pub-id pub-id-type="pmid">32219357</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>I-C</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>HA</given-names></name><name><surname>Han</surname><given-names>S</given-names></name></person-group><article-title>COVID-19-related myocarditis in a 21-year-old female patient</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>19</issue><fpage>1859</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehaa288</pub-id><?supplied-pmid 32282027?><pub-id pub-id-type="pmid">32282027</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name></person-group><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><?supplied-pmid 32192578?><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gazzaruso</surname><given-names>C</given-names></name><name><surname>Carlo Stella</surname><given-names>N</given-names></name><name><surname>Mariani</surname><given-names>G</given-names></name><etal/></person-group><article-title>High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia</article-title><source>Clin Rheumatol</source><year>2020</year><pub-id pub-id-type="doi">10.1007/s10067-020-05180-7</pub-id><?supplied-pmid 32548723?><pub-id pub-id-type="pmid">32548723</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harzallah</surname><given-names>I</given-names></name><name><surname>Debliquis</surname><given-names>A</given-names></name><name><surname>Dr&#x000e9;nou</surname><given-names>B</given-names></name></person-group><article-title>Lupus anticoagulant is frequent in patients with Covid-19</article-title><source>J Thromb Haemost</source><year>2020</year><pub-id pub-id-type="doi">10.1111/jth.14867</pub-id><?supplied-pmid 32608109?><pub-id pub-id-type="pmid">32608109</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Coagulopathy and antiphospholipid antibodies in patients with Covid-19</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>17</issue><fpage>e38</fpage><pub-id pub-id-type="doi">10.1056/NEJMc2007575</pub-id><pub-id pub-id-type="pmid">32268022</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title><source>Lancet Lond Engl</source><year>2020</year><volume>395</volume><issue>10229</issue><fpage>1054</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>S</given-names></name><name><surname>Noviello</surname><given-names>S</given-names></name><name><surname>Pagliano</surname><given-names>P</given-names></name></person-group><article-title>Update on treatment of COVID-19: ongoing studies between promising and disappointing results</article-title><source>Infez Med</source><year>2020</year><volume>28</volume><issue>2</issue><fpage>198</fpage><lpage>211</lpage><?supplied-pmid 32335561?><pub-id pub-id-type="pmid">32335561</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>Gratac&#x000f3;s</surname><given-names>J</given-names></name><name><surname>Tolosa</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><issue>3</issue><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1136/ard.2004.023200</pub-id><?supplied-pmid 16096334?><pub-id pub-id-type="pmid">16096334</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Shindo</surname><given-names>N</given-names></name></person-group><article-title>Influenza virus polymerase inhibitors in clinical development</article-title><source>Curr Opin Infect Dis</source><year>2019</year><volume>32</volume><issue>2</issue><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000532</pub-id><?supplied-pmid 30724789?><pub-id pub-id-type="pmid">30724789</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandwani</surname><given-names>A</given-names></name><name><surname>Shuter</surname><given-names>J</given-names></name></person-group><article-title>Lopinavir/ritonavir in the treatment of HIV-1 infection: a review</article-title><source>Ther Clin Risk Manag</source><year>2008</year><volume>4</volume><issue>5</issue><fpage>1023</fpage><lpage>1033</lpage><?supplied-pmid 19209283?><pub-id pub-id-type="pmid">19209283</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naik</surname><given-names>GS</given-names></name><name><surname>Tyagi</surname><given-names>MG</given-names></name></person-group><article-title>A pharmacological profile of ribavirin and monitoring of its plasma concentration in Chronic Hepatitis C Infection</article-title><source>J Clin Exp Hepatol</source><year>2012</year><volume>2</volume><issue>1</issue><fpage>42</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/S0973-6883(12)60090-5</pub-id><?supplied-pmid 25755405?><pub-id pub-id-type="pmid">25755405</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Psarras</surname><given-names>A</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Vital</surname><given-names>EM</given-names></name></person-group><article-title>Type I interferon&#x02013;mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy</article-title><source>Rheumatology</source><year>2017</year><volume>56</volume><issue>10</issue><fpage>1662</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kew431</pub-id><?supplied-pmid 28122959?><pub-id pub-id-type="pmid">28122959</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>4</issue><fpage>844</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/jth.14768</pub-id><?supplied-pmid 32073213?><pub-id pub-id-type="pmid">32073213</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wichmann</surname><given-names>D</given-names></name><name><surname>Sperhake</surname><given-names>J-P</given-names></name><name><surname>L&#x000fc;tgehetmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Autopsy findings and venous thromboembolism in patients With COVID-19</article-title><source>Ann Intern Med</source><year>2020</year><pub-id pub-id-type="doi">10.7326/M20-2003</pub-id><?supplied-pmid 32374815?><pub-id pub-id-type="pmid">32374815</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Thachil</surname><given-names>J</given-names></name><name><surname>Iba</surname><given-names>T</given-names></name><name><surname>Levy</surname><given-names>JH</given-names></name></person-group><article-title>Coagulation abnormalities and thrombosis in patients with COVID-19</article-title><source>Lancet Haematol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2352-3026(20)30145-9</pub-id><?supplied-pmid 32407672?><pub-id pub-id-type="pmid">32407672</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thachil</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name></person-group><article-title>SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism?</article-title><source>Semin Thromb Hemost</source><year>2020</year><pub-id pub-id-type="doi">10.1055/s-0040-1712155</pub-id><?supplied-pmid 32512589?><pub-id pub-id-type="pmid">32512589</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stockschlaeder</surname><given-names>M</given-names></name><name><surname>Schneppenheim</surname><given-names>R</given-names></name><name><surname>Budde</surname><given-names>U</given-names></name></person-group><article-title>Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis</article-title><source>Blood Coagul Fibrinolysis Int J Haemost Thromb</source><year>2014</year><volume>25</volume><issue>3</issue><fpage>206</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1097/MBC.0000000000000065</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Zuo</surname><given-names>M</given-names></name><name><surname>Yalavarthi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps and thrombosis in COVID-19</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.30.20086736</pub-id><?supplied-pmid 32587992?><pub-id pub-id-type="pmid">32587992</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name></person-group><article-title>Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy</article-title><source>J Thromb Haemost</source><year>2020</year><volume>18</volume><issue>5</issue><fpage>1094</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1111/jth.14817</pub-id><?supplied-pmid 32220112?><pub-id pub-id-type="pmid">32220112</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group><article-title>The mosaic of autoimmunity</article-title><source>Immunol Today</source><year>1989</year><volume>10</volume><issue>4</issue><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/0167-5699(89)90245-4</pub-id><?supplied-pmid 2665774?><pub-id pub-id-type="pmid">2665774</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arleevskaya</surname><given-names>MI</given-names></name><name><surname>Manukyan</surname><given-names>G</given-names></name><name><surname>Inoue</surname><given-names>R</given-names></name><name><surname>Aminov</surname><given-names>R</given-names></name></person-group><article-title>Editorial: microbial and environmental factors in autoimmune and inflammatory diseases</article-title><source>Front Immunol</source><year>2017</year><pub-id pub-id-type="doi">10.3389/fimmu.2017.00243</pub-id><?supplied-pmid 29259607?><pub-id pub-id-type="pmid">29259607</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toplak</surname><given-names>N</given-names></name><name><surname>Av&#x0010d;in</surname><given-names>T</given-names></name></person-group><article-title>Influenza and autoimmunity</article-title><source>Ann N Y Acad Sci</source><year>2009</year><volume>1173</volume><issue>1</issue><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04759.x</pub-id><?supplied-pmid 19758207?><pub-id pub-id-type="pmid">19758207</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta-Ampudia</surname><given-names>Y</given-names></name><name><surname>Monsalve</surname><given-names>DM</given-names></name><name><surname>Castillo-Medina</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Autoimmune neurological conditions associated with zika virus infection</article-title><source>Front Mol Neurosci</source><year>2018</year><pub-id pub-id-type="doi">10.3389/fnmol.2018.00116</pub-id><?supplied-pmid 29695953?><pub-id pub-id-type="pmid">29695953</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanay</surname><given-names>A</given-names></name></person-group><article-title>Chikungunya virus and autoimmunity</article-title><source>Curr Opin Rheumatol</source><year>2017</year><volume>29</volume><issue>4</issue><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000396</pub-id><?supplied-pmid 28376065?><pub-id pub-id-type="pmid">28376065</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fausther-Bovendo</surname><given-names>H</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>McCorrister</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ebola virus infection induces autoimmunity against dsDNA and HSP60</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>42147</fpage><pub-id pub-id-type="doi">10.1038/srep42147</pub-id><?supplied-pmid 28181533?><pub-id pub-id-type="pmid">28181533</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujinami</surname><given-names>RS</given-names></name><name><surname>von Herrath</surname><given-names>MG</given-names></name><name><surname>Christen</surname><given-names>U</given-names></name><name><surname>Whitton</surname><given-names>JL</given-names></name></person-group><article-title>Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease</article-title><source>Clin Microbiol Rev</source><year>2006</year><volume>19</volume><issue>1</issue><fpage>80</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1128/CMR.19.1.80-94.2006</pub-id><?supplied-pmid 16418524?><pub-id pub-id-type="pmid">16418524</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smatti</surname><given-names>MK</given-names></name><name><surname>Cyprian</surname><given-names>FS</given-names></name><name><surname>Nasrallah</surname><given-names>GK</given-names></name><name><surname>Al Thani</surname><given-names>AA</given-names></name><name><surname>Almishal</surname><given-names>RO</given-names></name><name><surname>Yassine</surname><given-names>HM</given-names></name></person-group><article-title>Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms</article-title><source>Viruses</source><year>2019</year><volume>11</volume><issue>8</issue><fpage>762</fpage><pub-id pub-id-type="doi">10.3390/v11080762</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Kaistha</surname><given-names>SD</given-names></name><name><surname>Rouse</surname><given-names>BT</given-names></name></person-group><article-title>Viruses and autoimmunity</article-title><source>Autoimmunity</source><year>2006</year><volume>39</volume><issue>1</issue><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1080/08916930500484708</pub-id><?supplied-pmid 16455584?><pub-id pub-id-type="pmid">16455584</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cusick</surname><given-names>MF</given-names></name><name><surname>Libbey</surname><given-names>JE</given-names></name><name><surname>Fujinami</surname><given-names>RS</given-names></name></person-group><article-title>Molecular mimicry as a mechanism of autoimmune disease</article-title><source>Clin Rev Allergy Immunol</source><year>2012</year><volume>42</volume><issue>1</issue><fpage>102</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1007/s12016-011-8294-7</pub-id><?supplied-pmid 22095454?><pub-id pub-id-type="pmid">22095454</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons-Weiler</surname><given-names>J</given-names></name></person-group><article-title>Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity</article-title><source>J Transl Autoimmun</source><year>2020</year><volume>3</volume><fpage>100051</fpage><pub-id pub-id-type="doi">10.1016/j.jtauto.2020.100051</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Megremis</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>TDJ</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group><article-title>Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis</article-title><source>Ann Rheum Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217522</pub-id><?supplied-pmid 32444414?><pub-id pub-id-type="pmid">32444414</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><article-title>SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon</article-title><source>Curr Opin Virol</source><year>2012</year><volume>2</volume><issue>3</issue><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2012.04.004</pub-id><?supplied-pmid 22572391?><pub-id pub-id-type="pmid">22572391</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>JK</given-names></name><name><surname>Maden</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Human leukocyte antigen susceptibility map for SARS-CoV-2</article-title><source>J Virol</source><year>2020</year><pub-id pub-id-type="doi">10.1128/JVI.00510-20</pub-id><?supplied-pmid 32321819?><pub-id pub-id-type="pmid">32321819</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charfi</surname><given-names>A</given-names></name><name><surname>Mahfoudh</surname><given-names>N</given-names></name><name><surname>Kamoun</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of HLA Alleles with Primary Sj&#x000f6;gren Syndrome in the South Tunisian Population</article-title><source>Med Princ Pract</source><year>2020</year><volume>29</volume><issue>1</issue><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1159/000501896</pub-id><?supplied-pmid 31272097?><pub-id pub-id-type="pmid">31272097</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choukri</surname><given-names>F</given-names></name><name><surname>Chakib</surname><given-names>A</given-names></name><name><surname>Himmich</surname><given-names>H</given-names></name><name><surname>H&#x000fc;e</surname><given-names>S</given-names></name><name><surname>Caillat-Zucman</surname><given-names>S</given-names></name></person-group><article-title>HLA-B&#x02217;51 and B&#x02217;15 alleles confer predisposition to Beh&#x000e7;et&#x02019;s disease in Moroccan patients</article-title><source>Hum Immunol</source><year>2001</year><volume>62</volume><issue>2</issue><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/S0198-8859(00)00249-4</pub-id><?supplied-pmid 11182229?><pub-id pub-id-type="pmid">11182229</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>PV</given-names></name><name><surname>Targoni</surname><given-names>OS</given-names></name><name><surname>Forsthuber</surname><given-names>TG</given-names></name></person-group><article-title>Shifting T-cell activation thresholds in autoimmunity and determinant spreading</article-title><source>Immunol Rev</source><year>1998</year><volume>164</volume><issue>1</issue><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.1998.tb01207.x</pub-id><?supplied-pmid 9795763?><pub-id pub-id-type="pmid">9795763</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokolove</surname><given-names>J</given-names></name><name><surname>Bromberg</surname><given-names>R</given-names></name><name><surname>Deane</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis</article-title><source>PLoS ONE</source><year>2012</year><pub-id pub-id-type="doi">10.1371/journal.pone.0035296</pub-id><?supplied-pmid 22662108?><pub-id pub-id-type="pmid">22662108</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>US</given-names></name><name><surname>Gaskin</surname><given-names>F</given-names></name><name><surname>Lewis</surname><given-names>JE</given-names></name><name><surname>Kannapell</surname><given-names>CC</given-names></name><name><surname>Fu</surname><given-names>SM</given-names></name></person-group><article-title>Mechanisms of autoantibody diversification to SLE-related autoantigens</article-title><source>Ann N Y Acad Sci</source><year>2003</year><volume>987</volume><issue>1</issue><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2003.tb06036.x</pub-id><?supplied-pmid 12727627?><pub-id pub-id-type="pmid">12727627</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbuckle</surname><given-names>MR</given-names></name><name><surname>McClain</surname><given-names>MT</given-names></name><name><surname>Rubertone</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Development of autoantibodies before the clinical onset of systemic lupus erythematosus</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><issue>16</issue><fpage>1526</fpage><lpage>1533</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021933</pub-id><?supplied-pmid 14561795?><pub-id pub-id-type="pmid">14561795</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>MS</given-names></name><name><surname>Bradley</surname><given-names>LM</given-names></name><name><surname>Harbertson</surname><given-names>J</given-names></name><name><surname>Krahl</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Sarvennick</surname><given-names>N</given-names></name></person-group><article-title>Diabetes induced by Coxsackie virus: Initiation by bystander damage and not molecular mimicry</article-title><source>Nat Med</source><year>1998</year><volume>4</volume><issue>7</issue><fpage>781</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1038/nm0798-781</pub-id><?supplied-pmid 9662368?><pub-id pub-id-type="pmid">9662368</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>L</given-names></name><name><surname>Tsunoda</surname><given-names>I</given-names></name><name><surname>Fujinami</surname><given-names>RS</given-names></name></person-group><article-title>Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation</article-title><source>Autoimmunity</source><year>2006</year><volume>39</volume><issue>1</issue><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1080/08916930500484799</pub-id><?supplied-pmid 16455578?><pub-id pub-id-type="pmid">16455578</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Hiroishi</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>T</given-names></name><etal/></person-group><article-title>Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL</article-title><source>J Immunol</source><year>1997</year><volume>158</volume><issue>11</issue><fpage>5283</fpage><lpage>5291</lpage><?supplied-pmid 9164947?><pub-id pub-id-type="pmid">9164947</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wucherpfennig</surname><given-names>KW</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name></person-group><article-title>Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein</article-title><source>Cell</source><year>1995</year><volume>80</volume><issue>5</issue><fpage>695</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90348-8</pub-id><?supplied-pmid 7534214?><pub-id pub-id-type="pmid">7534214</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Loustaud-Ratti</surname><given-names>V</given-names></name><name><surname>De Vita</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sj&#x000f6;gren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases</article-title><source>Medicine (Baltimore)</source><year>2005</year><volume>84</volume><issue>2</issue><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1097/01.md.0000157397.30055.c9</pub-id><pub-id pub-id-type="pmid">15758837</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Carrasco</surname><given-names>M</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Font</surname><given-names>J</given-names></name></person-group><article-title>Sj&#x000f6;gren&#x02019;s syndrome and hepatitis C virus</article-title><source>Clin Rheumatol</source><year>1999</year><volume>18</volume><issue>2</issue><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1007/s100670050064</pub-id><?supplied-pmid 10357112?><pub-id pub-id-type="pmid">10357112</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Functional exhaustion of antiviral lymphocytes in COVID-19 patients</article-title><source>Cell Mol Immunol</source><year>2020</year><volume>17</volume><issue>5</issue><fpage>533</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0402-2</pub-id><?supplied-pmid 32203188?><pub-id pub-id-type="pmid">32203188</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan</article-title><source>China The Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Ko</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea</article-title><source>J Korean Med Sci</source><year>2020</year><volume>35</volume><issue>7</issue><fpage>e86</fpage><pub-id pub-id-type="doi">10.3346/jkms.2020.35.e86</pub-id><?supplied-pmid 32080991?><pub-id pub-id-type="pmid">32080991</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrenfeld</surname><given-names>M</given-names></name><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Andreoli</surname><given-names>L</given-names></name><etal/></person-group><article-title>Covid-19 and autoimmunity</article-title><source>Autoimmun Rev</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.autrev.2020.102597</pub-id><?supplied-pmid 32535093?><pub-id pub-id-type="pmid">32535093</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podolska</surname><given-names>MJ</given-names></name><name><surname>Biermann</surname><given-names>MH</given-names></name><name><surname>Mauer&#x000f6;der</surname><given-names>C</given-names></name><name><surname>Hahn</surname><given-names>J</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name></person-group><article-title>Inflammatory etiopathogenesis of systemic lupus erythematosus: an update</article-title><source>J Inflamm Res</source><year>2015</year><volume>8</volume><fpage>161</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.2147/JIR.S70325</pub-id><?supplied-pmid 26316795?><pub-id pub-id-type="pmid">26316795</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matteucci</surname><given-names>D</given-names></name><name><surname>Paglianti</surname><given-names>M</given-names></name><name><surname>Giangregorio</surname><given-names>AM</given-names></name><name><surname>Capobianchi</surname><given-names>MR</given-names></name><name><surname>Dianzani</surname><given-names>F</given-names></name><name><surname>Bendinelli</surname><given-names>M</given-names></name></person-group><article-title>Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines</article-title><source>J Virol</source><year>1985</year><volume>56</volume><issue>2</issue><fpage>651</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1128/JVI.56.2.651-654.1985</pub-id><pub-id pub-id-type="pmid">2997486</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanbo</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Adachi-Takasawa</surname><given-names>K</given-names></name><name><surname>Takada</surname><given-names>K</given-names></name></person-group><article-title>Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt&#x02019;s lymphoma</article-title><source>EMBO J</source><year>2002</year><volume>21</volume><issue>5</issue><fpage>954</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.5.954</pub-id><?supplied-pmid 11867523?><pub-id pub-id-type="pmid">11867523</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nat Rev Microbiol</source><year>2016</year><volume>14</volume><issue>8</issue><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><?supplied-pmid 27344959?><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Yalavarthi</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps in COVID-19</article-title><source>JCI Insight</source><year>2020</year><pub-id pub-id-type="doi">10.1172/jci.insight.138999</pub-id><?supplied-pmid 32530438?><pub-id pub-id-type="pmid">32530438</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papayannopoulos</surname><given-names>V</given-names></name></person-group><article-title>Neutrophil extracellular traps in immunity and disease</article-title><source>Nat Rev Immunol</source><year>2018</year><volume>18</volume><issue>2</issue><fpage>134</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.105</pub-id><?supplied-pmid 28990587?><pub-id pub-id-type="pmid">28990587</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigerblad</surname><given-names>G</given-names></name><name><surname>Kaplan</surname><given-names>MJ</given-names></name></person-group><article-title>NETs spread ever wider in rheumatic diseases</article-title><source>Nat Rev Rheumatol</source><year>2020</year><volume>16</volume><issue>2</issue><fpage>73</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/s41584-019-0352-1</pub-id><?supplied-pmid 31853047?><pub-id pub-id-type="pmid">31853047</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan</article-title><source>China JAMA</source><year>2020</year><volume>323</volume><issue>11</issue><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papayannopoulos</surname><given-names>V</given-names></name><name><surname>Metzler</surname><given-names>KD</given-names></name><name><surname>Hakkim</surname><given-names>A</given-names></name><name><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group><article-title>Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps</article-title><source>J Cell Biol</source><year>2010</year><volume>191</volume><issue>3</issue><fpage>677</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1083/jcb.201006052</pub-id><?supplied-pmid 20974816?><pub-id pub-id-type="pmid">20974816</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>CY</given-names></name><name><surname>Lam</surname><given-names>KBH</given-names></name><name><surname>Ho</surname><given-names>P</given-names></name></person-group><article-title>Monitoring respiratory infections in covid-19 epidemics</article-title><source>BMJ</source><year>2020</year><pub-id pub-id-type="doi">10.1136/bmj.m1628</pub-id><?supplied-pmid 32366507?><pub-id pub-id-type="pmid">32366507</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>MG</given-names></name><name><surname>Gurney</surname><given-names>J</given-names></name><name><surname>Oliver</surname><given-names>J</given-names></name><etal/></person-group><article-title>Risk factors for acute rheumatic fever: literature review and protocol for a case-control study in New Zealand</article-title><source>Int J Environ Res Public Health</source><year>2019</year><pub-id pub-id-type="doi">10.3390/ijerph16224515</pub-id><?supplied-pmid 31731673?><pub-id pub-id-type="pmid">31731673</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiemsma</surname><given-names>LT</given-names></name><name><surname>Reynolds</surname><given-names>LA</given-names></name><name><surname>Turvey</surname><given-names>SE</given-names></name><name><surname>Finlay</surname><given-names>BB</given-names></name></person-group><article-title>The hygiene hypothesis: current perspectives and future therapies</article-title><source>Immunotargets Ther</source><year>2015</year><volume>4</volume><fpage>143</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.2147/ITT.S61528</pub-id><?supplied-pmid 27471720?><pub-id pub-id-type="pmid">27471720</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bach</surname><given-names>J-F</given-names></name></person-group><article-title>The hygiene hypothesis in autoimmunity: the role of pathogens and commensals</article-title><source>Nat Rev Immunol</source><year>2018</year><volume>18</volume><issue>2</issue><fpage>105</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.111</pub-id><?supplied-pmid 29034905?><pub-id pub-id-type="pmid">29034905</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manasson</surname><given-names>J</given-names></name><name><surname>Blank</surname><given-names>RB</given-names></name><name><surname>Scher</surname><given-names>JU</given-names></name></person-group><article-title>The microbiome in rheumatology: where are we and where should we go?</article-title><source>Ann Rheum Dis</source><year>2020</year><volume>79</volume><issue>6</issue><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2019-216631</pub-id><?supplied-pmid 32332073?><pub-id pub-id-type="pmid">32332073</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stojanovich</surname><given-names>L</given-names></name><name><surname>Marisavljevich</surname><given-names>D</given-names></name></person-group><article-title>Stress as a trigger of autoimmune disease</article-title><source>Autoimmun Rev</source><year>2008</year><volume>7</volume><issue>3</issue><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2007.11.007</pub-id><?supplied-pmid 18190880?><pub-id pub-id-type="pmid">18190880</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Andreadakis</surname><given-names>Z</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><etal/></person-group><article-title>The COVID-19 vaccine development landscape</article-title><source>Nat Rev Drug Discov</source><year>2020</year><volume>19</volume><issue>5</issue><fpage>305</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id><pub-id pub-id-type="pmid">32273591</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>SS</given-names></name><name><surname>Volkmuth</surname><given-names>W</given-names></name><name><surname>Duca</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2</article-title><source>Sci Transl Med</source><year>2015</year><volume>7</volume><issue>294</issue><fpage>294ra105</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aab2354</pub-id><?supplied-pmid 26136476?><pub-id pub-id-type="pmid">26136476</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>AS</given-names></name><name><surname>Tao</surname><given-names>X</given-names></name><name><surname>Algaissi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Hum Vaccines Immunother</source><year>2016</year><volume>12</volume><issue>9</issue><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1177688</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deming</surname><given-names>D</given-names></name><name><surname>Sheahan</surname><given-names>T</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants</article-title><source>PLoS Med</source><year>2006</year><volume>3</volume><issue>12</issue><fpage>e525</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0030525</pub-id><?supplied-pmid 17194199?><pub-id pub-id-type="pmid">17194199</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Coronavirus infections and immune responses</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1002/jmv.25685</pub-id><?supplied-pmid 31981224?><pub-id pub-id-type="pmid">31981224</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>HK</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name></person-group><article-title>COVID-19 Illness in Native and Immunosuppressed States: a clinical-therapeutic staging proposal</article-title><source>J Heart Lung Transpl</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.healun.2020.03.012</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f6;nmez</surname><given-names>HE</given-names></name><name><surname>Demir</surname><given-names>S</given-names></name><name><surname>Bilginer</surname><given-names>Y</given-names></name><name><surname>&#x000d6;zen</surname><given-names>S</given-names></name></person-group><article-title>Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature</article-title><source>Clin Rheumatol</source><year>2018</year><volume>37</volume><issue>12</issue><fpage>3329</fpage><lpage>3335</lpage><pub-id pub-id-type="doi">10.1007/s10067-018-4095-1</pub-id><?supplied-pmid 29663156?><pub-id pub-id-type="pmid">29663156</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santomasso</surname><given-names>B</given-names></name><name><surname>Bachier</surname><given-names>C</given-names></name><name><surname>Westin</surname><given-names>J</given-names></name><name><surname>Rezvani</surname><given-names>K</given-names></name><name><surname>Shpall</surname><given-names>EJ</given-names></name></person-group><article-title>The other side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden</article-title><source>Am Soc Clin Oncol Educ Book</source><year>2019</year><volume>39</volume><fpage>433</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1200/EDBK_238691</pub-id><?supplied-pmid 31099694?><pub-id pub-id-type="pmid">31099694</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huet</surname><given-names>T</given-names></name><name><surname>Beaussier</surname><given-names>H</given-names></name><name><surname>Voisin</surname><given-names>O</given-names></name><etal/></person-group><article-title>Anakinra for severe forms of COVID-19: a cohort study</article-title><source>Lancet Rheumatol</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30164-8</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGonagle</surname><given-names>D</given-names></name><name><surname>Sharif</surname><given-names>K</given-names></name><name><surname>O&#x02019;Regan</surname><given-names>A</given-names></name><name><surname>Bridgewood</surname><given-names>C</given-names></name></person-group><article-title>The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease</article-title><source>Autoimmun Rev</source><year>2020</year><volume>19</volume><issue>6</issue><fpage>102537</fpage><pub-id pub-id-type="doi">10.1016/j.autrev.2020.102537</pub-id><?supplied-pmid 7195002?><pub-id pub-id-type="pmid">32251717</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>E</given-names></name><name><surname>Sugawara</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>A</given-names></name><name><surname>Oda</surname><given-names>A</given-names></name><name><surname>Terai</surname><given-names>C</given-names></name></person-group><article-title>Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset still&#x02019;s disease: a case-based review</article-title><source>Case Rep Med</source><year>2016</year><volume>2016</volume><fpage>5656320</fpage><pub-id pub-id-type="doi">10.1155/2016/5656320</pub-id><?supplied-pmid 27688774?><pub-id pub-id-type="pmid">27688774</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effective treatment of severe COVID-19 patients with tocilizumab</article-title><source>Proc Natl Acad Sci</source><year>2020</year><volume>117</volume><issue>20</issue><fpage>10970</fpage><lpage>10975</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005615117</pub-id><pub-id pub-id-type="pmid">32350134</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantini</surname><given-names>F</given-names></name><name><surname>Niccoli</surname><given-names>L</given-names></name><name><surname>Matarrese</surname><given-names>D</given-names></name><name><surname>Nicastri</surname><given-names>E</given-names></name><name><surname>Stobbione</surname><given-names>P</given-names></name><name><surname>Goletti</surname><given-names>D</given-names></name></person-group><article-title>Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact</article-title><source>J Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jinf.2020.04.017</pub-id><?supplied-pmid 32592703?><pub-id pub-id-type="pmid">32592703</pub-id></element-citation></ref></ref-list></back></article>